DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs
NCT06329908
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Interventions
DRUG:
LG002
Sponsor
Zhen-Yu Ding